The Effect of Platelet Rich Plasma for the Treatment of Osteochondral Lesions of the Talus

NCT05795660 | Not Yet Recruiting Phase 1

• 1 other identifier: 1736/2021
• Study Type: interventional
• Target: 24
• Locations: 0 countries
• Sites: N/A

Brief Summary

Osteochondral lesion of the talus (OCL) results from the detachment of the talar cartilage which could also be associated with subchondral bone fragmentation due to trauma. OCL can be managed conservatively by immobilization and weight bearing restriction or surgically to stimulate the regeneration and the formation of fibrous cartilage including reparative or replacement approaches. OCL surgical intervention includes bone marrow stimulation or autologous osteochondral transplantation while the cartilage regeneration was found unsatisfactory with these interventions. However, introducing platelet rich plasma (PRP) as an adjacent intervention could enhance the cartilage regeneration in OCL due to the release of growth factors and bioactive components, which could in turn reduce the need for replacement interventions and improve the regeneration of the cartilage. The literature was reviewed, and four randomized controlled trials have been found exploring the effect of PRP in OCL where both ankle function and pain were examined. The results of the previous studies have proved the effectiveness of PRP in managing OCL as an adjunct to microfracture surgery in improving ankle function and reducing pain which was superior to the surgical intervention alone and also superior to the injection of PRP alone. Despite the promising results, the previous studies were limited to several factors. There was a lack of blinding which could risk the results to expectation bias, and the follow up period was short in according to the MCMS, which is needed to monitor the long-term effect of the PRP and to document any potential adverse effects or relapse in the function. Additionally, all the previous studies performed blind injection. Additionally, the previous studies have not controlled the administration of analgesic which could risk the results of the pain effect. The proposed study aims to examine the effect of PRP in the management of OCL using randomized double-blind control trial design to eliminate any expectation bias. Patients will be followed up for 12 months, and the PRP will be administered intra-operatively. Moreover, PRP concentration will be standardized. Analgesic will be controlled and documented as a confounded factor. Additionally, the quality of the repaired tissue and the regeneration of the hyaline cartilage will be examined using MRI at the end of the follow-up. Therefore, the study aims to examine the effectiveness of PRP in OCL using randomized controlled trial design.

Conditions

Osteochondral Lesions of the Talus

Outcome Measures

Primary Outcomes (1)

• American Orthopedic Foot and Ankle (AOFAS) score

  12 months

Study Arms (2)

Osteochondral lesions of the talus group

EXPERIMENTAL

Patients will receive PRP injection.

Biological: platelet rich plasma

Control group

PLACEBO COMPARATOR

Patients will receive saline injection.

Biological: platelet rich plasma

Interventions

platelet rich plasma BIOLOGICAL

platelet rich plasma injection

Also known as: platelet rich plasma injection

Control group; Osteochondral lesions of the talus group

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Diagnosis of OCL, which will be confirmed with radiographs and magnetic resonance imaging.
• aged \> or = 18 years \< 60 year
• complain of ankle pain.

You may not qualify if:

• posterior OCL
• pregnancy
• ankle infection
• teroid injection within 6 months
• surgery of the involved joint with 6 months
• received glucosamine and/or chondroitin sulfate, or anticoagulant
• Systematic inflammatory condition
• substantial venous or lymphatic stasis in the legs
• Pathologies that my confound pain and functional assessment in the ankle (plantar fasciitis, Achilles tendonitis, sprains, and degenerative joint disease of the foot.
• Allergy to any of the component of the PRP injection, disabling degenerative joint disease.

Sponsors & Collaborators

• Ministry of Health, Kuwait: lead

Central Study Contacts

Najla Alsiri, PhD

CONTACT

00965-66820032; dr.alsiri@outlook.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head of Orthopedic Surgery Department

Study Record Dates

• First Submitted: November 16, 2022
• First Posted: April 3, 2023
• Study Start: April 1, 2023
• Primary Completion: December 1, 2025
• Study Completion (Estimated): December 1, 2026
• Last Updated: April 3, 2023

Record last verified: 2023-03